Keytruda + Lenvima meet PFS primary endpoint in advanced RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase III trial, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) met the primary endpoint of progression-free survival as first-line treatment of advanced renal cell carcinoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login